Published Data in The Lancet Diabetes & Endocrinology Highlights Unique Efficacy Benefits of Sotagliflozin to Reduce Major Adverse Cardiovascular Events (MACE)

Core Insights - The article highlights the unique clinical advantages of sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, in reducing life-threatening cardiovascular outcomes compared to empagliflozin [2][3] - A published study in The Lancet Diabetes & Endocrinology confirms the ischemic benefits of sotagliflozin, showing significant reductions in major adverse cardiovascular events (MACE), myocardial infarction (MI), and stroke among patients with type 2 diabetes (T2D), chronic kidney disease (CKD), and high cardiovascular risk [3][5] Study Findings - The study titled "Reduction in Major Adverse Cardiovascular Events with Sotagliflozin" is a secondary analysis of the SCORED trial, which was a double-blind, placebo-controlled, randomized clinical trial [4] - Sotagliflozin demonstrated a lower rate of MACE outcomes at 4.8 events per 100 person-years compared to 6.3 events per 100 person-years in the placebo group, with a hazard ratio of 0.77 [5] - The reduction in MI was significant, with 1.8 events per 100 person-years in the sotagliflozin group versus 2.7 events per 100 person-years in the placebo group, yielding a hazard ratio of 0.68 [5] - Stroke rates were also lower in the sotagliflozin group at 1.2 events per 100 person-years compared to 1.8 events per 100 person-years in the placebo group, with a hazard ratio of 0.66 [5] Expert Commentary - Dr. Deepak L. Bhatt emphasized that sotagliflozin is the only SGLT inhibitor to show significant reductions in both heart attack and stroke [6] - Craig Granowitz, M.D., noted that the comprehensive findings illustrate how sotagliflozin stands apart from other SGLT inhibitors [7] Company Overview - Lexicon Pharmaceuticals is focused on pioneering medicines that transform patients' lives, utilizing its Genome5000™ program to discover therapeutic targets [9] - The company has a pipeline of drug candidates in various stages of development, addressing conditions such as neuropathic pain, hypertrophic cardiomyopathy, and obesity [9]